Meeting
2018 ASCO Annual Meeting
Differences in survival outcomes in advanced endometrial cancer due to variation in adjuvant therapy and histology.
Authors
Emily Meichun Ko
University of Pennsylvania, Philadelphia, PA
Emily Meichun Ko , Colleen Brensinger , Diego J Aviles , Ashley Ford Haggerty , Robert Lawrence Giuntoli II, Nawar A. Latif , Mark Aloysuis Morgan , Lilie L. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5588)
DOI
10.1200/JCO.2018.36.15_suppl.5588
Abstract #
5588
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Role of adjuvant chemoradiation in treatment of elderly women with advanced high-grade endometrial cancer: A SEER-Medicare analysis.
First Author: Hyo K. Park
Poster
2023 ASCO Annual Meeting
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
First Author: Florence Joly
Poster
2022 ASCO Annual Meeting
Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.
First Author: Robert L. Coleman
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda